Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

NCT01489722 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: AZD1208

Sponsor

AstraZeneca